Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Kwan Sik LeeYoung-Oh KweonSoon-Ho UmByung-Ho KimYoung Suk LimSeung Woon PaikJeong HeoHeon-Ju LeeDong Joon KimTae Hun KimYoung-Sok LeeKwan Soo ByunDaeghon KimMyung Seok LeeKyungha YuDong Jin SuhPublished in: Clinical and molecular hepatology (2017)
Long-term ETV treatment was superior to LAM, with a significantly higher proportion of patients achieving VR. Both treatments were well tolerated.